PinPoint Get PinPoint on the App Store

GLP-1 & metabolic / Compound guide

Semaglutide guide

Semaglutide is a GLP-1 receptor agonist studied for blood-glucose control, with products including Ozempic, Wegovy, and Rybelsus.[2] This guide follows the generic molecule in PinPoint's library and the subcutaneous reference used for its tracking model.[1]

PINPOINT EDITORIAL · UPDATED 05 OCT 2026
FDA-labeled presentation · 168 h model input

Editorial still life for glp-1 & metabolic research guides

ILLUSTRATION / COMPOUND LIBRARY SERIES

At a glance

Semaglutide library factsGLP-1 & metabolic. Routes: subcutaneous. Half-life model input: 168 hours. Package: 10 mg / package. FDA-labeled presentation. CATEGORYROUTES IN LIBRARYHALF-LIFE MODEL INPUTTYPICAL PACKAGERESEARCH STATUS GLP-1 & metabolicsubcutaneous168 hours10 mg / packageFDA-labeled presentation SOURCE / PINPOINT COMPOUND LIBRARY

Read the record in context

This semaglutide record is anchored to the injected molecule. Its weekly timing reference and historical 10 mg catalog package come from different documents. The catalog link is currently unverified; the amount above is only a library snapshot. The separately labeled pen example below does not validate this research vial.[1]

What the research says

The Ozempic prescribing information describes subcutaneous pharmacokinetic studies in people with type 2 diabetes. Researchers measured circulating semaglutide concentrations to estimate exposure, clearance, and distribution. Exposure increased proportionally across the studied weekly strengths; the label reports an elimination half-life of approximately one week.[2][1]

Absorption measurements showed 89% absolute bioavailability and peak concentrations one to three days after injection. Exposure was similar across abdomen, thigh, and upper-arm injection sites. These findings concern the injectable formulation described in the label, including its route and study population.[2]

The label also describes extensive albumin binding and breakdown through cleavage of the peptide backbone and fatty-acid sidechain. Semaglutide-related material leaves through urine and feces, with only a small fraction excreted intact. Oral products have their own absorption characteristics; this injectable reference does not characterize them.[2]

Cited amounts

The separately labeled Ozempic pen presentation contains 4 mg in 3 mL. This is a prepared liquid product, not the research-catalog vial preserved in At a glance. The original supplier link could not be verified, so its package amount is not used for a worked calculation.[6][1]

Explore the Semaglutide dosing chart

Half-life and timing

A seven-day interval contains 168 hours. Following one hypothetical starting amount across two such intervals gives 25% at 336 hours; across three gives 12.5% at 504 hours. The five-interval endpoint is 840 hours, or 35 days, with 3.125% remaining. These percentages describe exponential arithmetic with the library input held constant. They leave out absorption and additional entries, and neither the endpoint nor the one-week label reference defines an individual's elimination time.[1][5]

Semaglutide: modeled fraction over five half-livesStarting at 100 percent, the model halves each 168 hours. After 840 hours, 3.125 percent remains. This is arithmetic, not a measured concentration. ELAPSED HOURS / MODELED STARTING AMOUNT 0 h100%168 h50%336 h25%504 h12.5%672 h6.25%840 h3.125% Explore the Semaglutide half-life model

Reconstitution

The primary worked example uses the Ozempic label: two pens containing 4 mg each represent 8 mg in total inventory. This count calculation leaves the prepared liquid and delivery device intact. It does not specify an administered amount, a pen setting, or water addition. The original supplier package remains an unverified library snapshot, and the approved label does not validate that research vial. Package arithmetic and device instructions have different purposes.[6]

2 pens × 4 mg = 8 mg
Open Semaglutide conversion math

Tracking it in PinPoint

From a reference to a record

Built for peptide, TRT, and GLP-1 schedules. Set up your vial in seconds, log every dose, and see your modeled levels between doses. Enter vial size in mg, mcg, or IU and water volume for instant concentration and syringe units. Track vials and prefilled pens side by side.[4]

The Home curve models your levels between doses from published half-life data. Drag to scrub modeled values at any timestamp, or preview 30 days of a dose pattern. Ask PinPoint provides educational reference with sources; it never recommends a dose or a schedule change. These features record and visualize entered information, with the limits of each compound's source data still applying.

Get PinPoint on the App Store

Frequently asked questions

Does a semaglutide mixing chart describe an Ozempic pen?
A powder-vial mixing chart and a prepared Ozempic pen describe different presentations. This guide uses a labeled pen-count example because the original research-catalog package could not be verified. Neither a generic molecule name nor arithmetic establishes that the two products have equivalent formulations.[6][1]
Can a semaglutide reconstitution calculator use the tablet reference?
The injection reference does not establish tablet absorption or liquid preparation. The primary example counts labeled pens and adds no water. A calculator cannot convert an oral product into an injectable presentation or supply a missing verified research-vial amount.[6][1][5]
Why does a semaglutide half-life page show a five-week endpoint?
Five repetitions of the stored seven-day interval equal 35 days. The model still retains one thirty-second of its starting amount there. That arithmetic endpoint is neither proof of zero remaining compound nor a personal instruction about waiting five weeks.[1][5]
Can a peptide tracker app record Semaglutide?
PinPoint's compound library includes Semaglutide. The app description covers logging compound, dose, site, and pain level, as well as viewing modeled levels between recorded doses. The curve uses published reference inputs and does not account for individual variation. The tracker records the schedule entered by its user; it does not choose a dose or recommend a schedule change.[1][4]

Sources

Facts and reference links were retrieved from the PinPoint application library on 5 October 2026. Links below preserve the library's citations; a catalog source supports a package amount only. Source references carried from the library have not all been independently reverified. Arithmetic examples are identified separately from clinical evidence.

  1. PinPoint compound library, SemaglutideSnapshot of the application library; its references and uncertainty are retained below.Retrieved 2026-10-05 · library
  2. DailyMed prescribing informationIdentity and research summary checked against this document on 5 October 2026. Clinical pharmacology and product-description sections.Retrieved 2026-10-05 · library-reference
  3. Supplier catalog package referenceUnverified package locator: the public link requires sign-in. The amount is retained only as a library snapshot in At a glance; it is not an externally verified package input.Retrieved 2026-10-05 · unverified-supplier
  4. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description
  5. Unit conversion and exponential-decay arithmeticC = amount / volume; remaining fraction = 2^(-elapsed / half-life). These are illustrations, not measurements.Retrieved 2026-10-05 · arithmetic
  6. Approved product label: package presentationVerified 5 October 2026. Separately labeled presentation; does not validate a research-catalog vial.Retrieved 2026-10-05 · product-label